- Home
- XPEL vs DAWN Comparison
XPEL vs DAWN Comparison
Compare XPEL & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEL | DAWN |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | XPEL | DAWN |
|---|---|---|
| Price | $54.78 | $11.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.56 |
| AVG Volume (30 Days) | 204.9K | ★ 2.6M |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $461,460,000.00 | $133,672,000.00 |
| Revenue This Year | $16.20 | $18.27 |
| Revenue Next Year | $11.28 | $48.39 |
| P/E Ratio | $31.90 | ★ N/A |
| Revenue Growth | 10.29 | ★ 31.11 |
| 52 Week Low | $24.25 | $5.64 |
| 52 Week High | $55.91 | $13.20 |
Technical Indicators
Market Signals| Indicator | XPEL | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 52.30 |
| Support Level | $50.35 | $10.76 |
| Resistance Level | $55.91 | $11.99 |
| Average True Range (ATR) | 1.84 | 0.68 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 60.25 | 38.41 |
Price Performance
Historical ComparisonAbout XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.